• slide
  • slide

Aktuelle Nutzenbewertungsverfahren

Hier finden Sie alle aktuellen Verfahren der Frühen Nutzenbewertung der letzten 12 Monate.

 

Ongoing (preliminary decision published)
Diroximel fumarate (relapsing-remitting multiple sclerosis)
Olaparib (new indication: metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and/or prednisone for patients in whom chemotherapy is not clinically indicated)
Maralixibat (Alagille syndrome (ALGS) patients aged ≥ 2 months
Lutetium (177Lu) vipivotide tetraxetan (progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) for patients who have progressed after treatment with AR pathway inhibition and taxane-based chemotherapy, in combination with androgen deprivation therapy (ADT))
Trastuzumab deruxtecan (new indication: breast cancer; HER2-low; pre-treated patients)
Trastuzumab deruxtecan (new indication: gastric or gastroesophageal junction (GEJ) adenocarcinoma; HER2-positive; after a trastuzumab-based regimen)
Spesolimab (generalized pustular psoriasis (GPP); acute treatment)
Ibrutinib (new indication: chronic lymphocytic leukemia (CLL); first line; in combination with venetoclax)
Sotorasib (re-assessment: non-small cell lung cancer (NSCLC); KRAS G12C mutation; ≥ 1 previous therapy)
Ciltacabtagene autoleucel (multiple myeloma, patients with at least three prior therapies)
Fenfluramine (new indication: Lennox-Gastaut syndrome as an add-on therapy for patients aged ≥ 2 years)
Dapagliflozin (new indication: chronic heart failure with left ventricular ejection fraction (LVEF) > 40 %)
Dolutegravir / abacavir / lamivudine (new indication: HIV infection; ≥ 14 kg and < 12 years of age)
Finerenone (chronic kidney disease associated with type 2 diabetes; stage 3 and 4 with albuminuria)
Finerenone (chronic kidney disease associated with type 2 diabetes; stage 1 and 2 with albuminuria)
Emicizumab (new indication: moderate hemophilia A; without factor VIII inhibitors; severe bleeding phenotype)
Voclosporin (lupus nephritis)
Esketamine (re-assessment: treatment-resistant Major Depressive Disorder in combination with a SSRI or SNRI)
Completed (final decision published)
07.07.2022
Lenvatinib (new indication: endometrial carcinoma, after platinum-based therapy, in combination with pembrolizumab)
07.07.2022
Lenvatinib (new indication: advanced renal cell carcinoma, 1st line, in combination with pembrolizumab)
07.07.2022
Pembrolizumab (new indication: advanced renal cell carcinoma, 1st line, in combination with lenvatinib)
16.06.2022
Dapagliflozin (new indication: type 2 diabetes mellitus, patients ≥ 10 years)
16.06.2022
Ozanimod (new indication: ulcerative colitis, pre-treated patients)
16.06.2022
Zanubrutinib (Waldenström's macroglobulinemia (WM), first-line treatment for patients unsuitable for chemo-immunotherapy or patients ≥ 1 previous therapy)
16.06.2022
Tofacitinib (new indication: ankylosing spondylitis)
16.06.2022
Pralsetinib (non-small cell lung cancer (NSCLC), RET-fusion-positive advanced)
16.06.2022
Idecabtagen vicleucel (multiple myeloma. ≥ 3 previous therapies)
16.06.2022
Evolocumab (new indication: primary hypercholesterolemia, patients from ≥ 10 to < 18 years)
16.06.2022
Ripretinib (gastrointestinal stromal tumor (GIST), ≥ 3 previous therapies)
19.05.2022
Abemaciclib (re-assessment: breast cancer, HR+, HER2- in combination with fulvestrant)
19.05.2022
Filgotinib (new indication: ulcerative colitis, pretreated patients)
19.05.2022
Mepolizumab (new indication: eosinophilic granulomatosis with polyangiitis (EGPA))
19.05.2022
Mepolizumab (new indication: chronic rhinosinusitis with nasal polyps)
19.05.2022
Mepolizumab (new indication: hypereosinophilic syndrome)
19.05.2022
Lusutrombopag (thrombocytopenia with chronic liver disease)
19.05.2022
Sacituzumab Govitecan (triple-negative breast cancer, ≥ 2 previous therapies)
19.05.2022
Risankizumab (new indication: psoriatic arthritis, monotherapy or in combination with methotrexate)
19.05.2022
Nivolumab (new indication: gastric, gastro-esophageal junction (GEJ) or esophageal adenocarcinoma, CPS ≥ 5 HER2-, first-line therapy in combination with fluoropyrimidine-and platinum-based combination chemotherapy)
19.05.2022
Ertugliflozin (type 2 diabetes mellitus)
19.05.2022
Ponesimod (relapsing forms of multiple sclerosis (RMS))
05.05.2022
Pembrolizumab (new indication: breast cancer, triple-negative, PD-L1 expression ≥ 10 (CPS), in combination with chemotherapy)
05.05.2022
Pembrolizumab (new indication: carcinoma of the esophagus or gastroesophageal junction, PD-L1 expression ≥ (CPS), 1st line, in combination with platinum- and fluoropyrimidine-based chemotherapy)
05.05.2022
Elbasvir / grazoprevir (new indication: chronic hepatitis C; adolescents from 12 to < 18 years)